Citi raised the firm’s price target on Ascendis Pharma (ASND) to $243 from $213 and keeps a Buy rating on the shares. The firm updated commercial stage biotechnology targets into the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Grants Warrants to Employees to Boost Engagement
- Positive Outlook for Ascendis Pharma Driven by Yorvipath’s Growing Adoption and Revenue Potential
- Ascendis Pharma assumed with an Overweight at Morgan Stanley
- Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
- Ascendis Pharma’s Competitive Edge in Achondroplasia Treatment: Buy Rating Supported by TransCon CNP’s Potential and Yorvipath Launch